These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 19407441)

  • 21. Incorporation of pharmacogenetic testing into medication therapy management.
    Haga SB; Moaddeb J; Mills R; Patel M; Kraus W; Allen LaPointe NM
    Pharmacogenomics; 2015 Nov; 16(17):1931-41. PubMed ID: 26555559
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Facilitators and Barriers to the Adoption of Pharmacogenetic Testing in an Inner-City Population.
    Lee YM; Manzoor BS; Cavallari LH; Nutescu EA
    Pharmacotherapy; 2018 Feb; 38(2):205-216. PubMed ID: 29286540
    [TBL] [Abstract][Full Text] [Related]  

  • 23. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility.
    American Society of Clinical Oncology
    J Clin Oncol; 2003 Jun; 21(12):2397-406. PubMed ID: 12692171
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of Previous Genetic Counseling and Objective Numeracy on Accurate Interpretation of a Pharmacogenetics Test Report.
    Drelles K; Pilarski R; Manickam K; Shoben AB; Toland AE
    Public Health Genomics; 2021; 24(1-2):26-32. PubMed ID: 33445171
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of a personal CYP2D6 testing workshop on physician assistant student attitudes toward pharmacogenetics.
    O'Brien TJ; LeLacheur S; Ward C; Lee NH; Callier S; Harralson AF
    Pharmacogenomics; 2016 Mar; 17(4):341-52. PubMed ID: 26907849
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Public perspectives about pharmacogenetic testing and managing ancillary findings.
    Haga SB; Tindall G; O'Daniel JM
    Genet Test Mol Biomarkers; 2012 Mar; 16(3):193-7. PubMed ID: 22047505
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Policy versus practice: comparison of prescribing therapy and durable medical equipment in medical and educational settings.
    Sneed RC; May WL; Stencel C
    Pediatrics; 2004 Nov; 114(5):e612-25. PubMed ID: 15520092
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Disparities in stroke symptomology knowledge among US midlife women: an analysis of population survey data.
    Lutfiyya MN; Ng L; Asner N; Lipsky MS
    J Stroke Cerebrovasc Dis; 2009; 18(2):150-7. PubMed ID: 19251192
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacogenetic testing in primary care practice: opinions of physicians, pharmacists and patients.
    Frigon MP; Blackburn MÈ; Dubois-Bouchard C; Gagnon AL; Tardif S; Tremblay K
    Pharmacogenomics; 2019 Jun; 20(8):589-598. PubMed ID: 31190623
    [No Abstract]   [Full Text] [Related]  

  • 30. Primary care physician experiences with integrated pharmacogenomic testing in a community health system.
    Lemke AA; Hutten Selkirk CG; Glaser NS; Sereika AW; Wake DT; Hulick PJ; Dunnenberger HM
    Per Med; 2017 Sep; 14(5):389-400. PubMed ID: 29754567
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacogenomic and pharmacogenetic-guided therapy as a tool in precision medicine: current state and factors impacting acceptance by stakeholders.
    Hess GP; Fonseca E; Scott R; Fagerness J
    Genet Res (Camb); 2015 Jun; 97():e13. PubMed ID: 26030725
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Non-interventional cardiologists' perspectives on the role of pharmacogenomic testing in cardiovascular medicine.
    Deininger KM; Page RL; Lee YM; Kauffman YS; Johnson SG; Oreschak K; Aquilante CL
    Per Med; 2019 Mar; 16(2):123-132. PubMed ID: 30543145
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Attitudes of Colorado health professionals toward breast and cervical cancer screening in Hispanic women.
    Bakemeier RF; Krebs LU; Murphy JR; Shen Z; Ryals T
    J Natl Cancer Inst Monogr; 1995; (18):95-100. PubMed ID: 8562228
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Factors affecting contraceptive use in women seeking pregnancy tests: Missouri, 1997.
    Sable MR; Libbus MK; Chiu JE
    Fam Plann Perspect; 2000; 32(3):124-31. PubMed ID: 10894258
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Women's interest in genetic testing for breast cancer risk: the influence of sociodemographics and knowledge.
    Bottorff JL; Ratner PA; Balneaves LG; Richardson CG; McCullum M; Hack T; Chalmers K; Buxton J
    Cancer Epidemiol Biomarkers Prev; 2002 Jan; 11(1):89-95. PubMed ID: 11815405
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Attitudes about genetics in underserved, culturally diverse populations.
    Catz DS; Green NS; Tobin JN; Lloyd-Puryear MA; Kyler P; Umemoto A; Cernoch J; Brown R; Wolman F
    Community Genet; 2005; 8(3):161-72. PubMed ID: 16113533
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A nationwide survey of pharmacists' perception of pharmacogenetics in the context of a clinical decision support system containing pharmacogenetics dosing recommendations.
    Bank PC; Swen JJ; Guchelaar HJ
    Pharmacogenomics; 2017 Feb; 18(3):215-225. PubMed ID: 28112992
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Patient perspectives following pharmacogenomics results disclosure in an integrated health system.
    Lemke AA; Hulick PJ; Wake DT; Wang C; Sereika AW; Yu KD; Glaser NS; Dunnenberger HM
    Pharmacogenomics; 2018 Mar; 19(4):321-331. PubMed ID: 29469671
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Healthcare provider and patient perspectives on the implementation of pharmacogenetic-guided treatment in routine clinical practice.
    Kaur G; Nwabufo CK
    Pharmacogenet Genomics; 2024 Sep; 34(7):236-245. PubMed ID: 38917295
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Harnessing economic drivers for successful clinical implementation of pharmacogenetic testing.
    Deverka PA; McLeod HL
    Clin Pharmacol Ther; 2008 Aug; 84(2):191-3. PubMed ID: 18679180
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.